A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Solid Malignancies · Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Ductal Adenocarcinoma (PDAC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Johns Hopkins Hospital, Baltimore, Maryland, United States
Contact: Study coordinator (Nilofer Azad) · 410-502-2995
NEXT Oncology, San Antonio, Texas, United States
Contact: Study coordinator (David Sommerhalder) · 210-580-9500
START Mountain Region, West Valley City, Utah, United States
Contact: Study coordinator (Justin Call) · 801-907-4750
NEXT Virginia, Fairfax, Virginia, United States
Contact: Study coordinator (Alexander Spira) · 703-280-5390
BC Cancer Vancouver, Vancouver, British Columbia, Canada
Contact: Study coordinator (Daniel Renouf) · 6048776000Ext3297
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (Albiruni Abdul Razak) · 6479709845
Local Institution - 0006, Badalona, Barcelona [Barcelona], Spain
Local Institution - 0008, Hortaleza, Madrid, Spain

Study leads

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

View source on ClinicalTrials.gov Contact study team (email)